Novavax Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

8 brokerages have issued twelve-month price objectives for Novavax's stock. Their NVAX stock forecasts range from $35.00 to $209.00. On average, they anticipate Novavax's stock price to reach $164.00 in the next twelve months. This suggests a possible upside of 131.4% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the beginning of the year. Since then, NVAX shares have decreased by 50.5% and is now trading at $70.88.
View the best growth stocks for 2022 here.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Monday, May, 9th. The biopharmaceutical company reported $2.56 EPS for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company earned $703.97 million during the quarter, compared to the consensus estimate of $845.20 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The firm's quarterly revenue was up 57.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($3.05) EPS.
View Novavax's earnings history.

Novavax's stock reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

Novavax updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by a variety of retail and institutional investors. Top institutional investors include CTC LLC (0.00%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including CTC LLC. Company insiders that have sold Novavax company stock in the last two years include David M Mott, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $70.88.

Novavax (NASDAQ:NVAX) has a market capitalization of $5.54 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.68) on an earnings per share basis.

Novavax employs 1,541 workers across the globe.

Novavax was founded in 1987.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for Novavax is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.